# Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans

> **NCT04313634** · PHASE2 · COMPLETED · sponsor: **Sundeep Khosla, M.D.** · enrollment: 74 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Quercetin
- **DRUG:** Fisetin

## Key facts

- **NCT ID:** NCT04313634
- **Lead sponsor:** Sundeep Khosla, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-09
- **Primary completion:** 2023-06-06
- **Final completion:** 2023-06-06
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2024-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04313634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04313634, "Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04313634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*